The Indian pharmaceutical industry is the third biggest in the world in terms of volume. The government has actively encouraged the growth of drug manufacturing within the country and has been providing many incentives to leading global manufacturers to set up their production hubs in India. Mumbai, Hyderabad, Bangalore, Ahmedabad and Visakhapatnam are some of the leading pharmaceutical hubs in the country.
The Indian generics industry has similarly experienced robust growth in the last couple of years and generics account for over 96% of the overall pharmaceutical market in India. The Indian Government's 'Pharma Vision 2020' has been a major factor towards the growth of the generics segment in the country.
Aruvian Research presents Analyzing Generics Market in India 2017 – a comprehensive coverage of the Indian generic drugs market. Beginning with a sectional description on the global generic industry, the report looks at an overview of the industry, an analysis of the market volume and value, industry segmentation and an industry forecast.
Moving on, we analyze the Generics Industry in Asia Pacific through the same parameters.
The Generics Industry in India is analyzed through an industry overview which spans the data from 2012 till 2021. An analysis of the industry's value and volume data is included along with an industry segmentation by geography. Industry forecast of the industry is also included.
We also include a Porter’s Five Forces analysis of the Indian Generics Industry. Generics pricing and reimbursement situation in India and trends and challenges facing the industry are analyzed.
Analysis of the major industry players in the Indian generics market are analyzed through an analysis of their business segments, a financial analysis and a SWOT analysis. Players analyzed include Cipla Limited, Lupin, Mylan, Sanofi SA, Teva Pharmaceutical Industries, Aurobindo Pharma Limited, Sun Pharmaceutical Industries Ltd. and Sandoz International. This concludes this comprehensive research report from Aruvian Research.